Xi Yang1, William F Salminen2, Qiang Shi3, James Greenhaw4, Pritmohinder S Gill5, Sudeepa Bhattacharyya6, Richard D Beger7, Donna L Mendrick8, William B Mattes9, Laura P James10. 1. Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, AR, USA. Electronic address: Xi.Yang@fda.hhs.gov. 2. Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, AR, USA. Electronic address: Willie.Salminen@parexel.com. 3. Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, AR, USA. Electronic address: Qiang.Shi@fda.hhs.gov. 4. Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, AR, USA. Electronic address: James.Greenhaw@fda.hhs.gov. 5. Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Clinical Pharmacology and Toxicology Section, Arkansas Children's Hospital, Little Rock, AR, USA. Electronic address: PSGill@uams.edu. 6. Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Clinical Pharmacology and Toxicology Section, Arkansas Children's Hospital, Little Rock, AR, USA. Electronic address: SBhattacharyya2@uams.edu. 7. Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, AR, USA. Electronic address: Richard.Beger@fda.hhs.gov. 8. Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, AR, USA. Electronic address: Donna.Mendrick@fda.hhs.gov. 9. Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, AR, USA. Electronic address: William.Mattes@fda.hhs.gov. 10. Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Clinical Pharmacology and Toxicology Section, Arkansas Children's Hospital, Little Rock, AR, USA. Electronic address: jameslaurap@uams.edu.
Abstract
UNLABELLED: Developing biomarkers for detecting acetaminophen (APAP) toxicity has been widely investigated. Recent studies of adults with APAP-induced liver injury have reported human serum microRNA-122 (miR-122) as a novel biomarker of APAP-induced liver injury. The goal of this study was to examine extracellular microRNAs (miRNAs) as potential biomarkers for APAP liver injury in children. Global levels of serum and urine miRNAs were examined in three pediatric subgroups: 1) healthy children (n=10), 2) hospitalized children receiving therapeutic doses of APAP (n=10) and 3) children hospitalized for APAP overdose (n=8). Out of 147 miRNAs detected in the APAP overdose group, eight showed significantly increased median levels in serum (miR-122, -375, -423-5p, -30d-5p, -125b-5p, -4732-5p, -204-5p, and -574-3p), compared to the other groups. Analysis of urine samples from the same patients had significantly increased median levels of four miRNAs (miR-375, -940, -9-3p and -302a) compared to the other groups. Importantly, correlation of peak serum APAP protein adduct levels (an indicator of the oxidation of APAP to the reactive metabolite N-acetyl-para-quinone imine) with peak miRNA levels showed that the highest correlation was observed for serum miR-122 (R=0.94; p<0.01) followed by miR-375 (R=0.70; p=0.05). CONCLUSION: Our findings demonstrate that miRNAs are increased in children with APAP toxicity and correlate with APAP protein adducts, suggesting a potential role as biomarkers of APAP toxicity. Published by Elsevier Inc.
UNLABELLED: Developing biomarkers for detecting acetaminophen (APAP) toxicity has been widely investigated. Recent studies of adults with APAP-induced liver injury have reported human serum microRNA-122 (miR-122) as a novel biomarker of APAP-induced liver injury. The goal of this study was to examine extracellular microRNAs (miRNAs) as potential biomarkers for APAPliver injury in children. Global levels of serum and urine miRNAs were examined in three pediatric subgroups: 1) healthy children (n=10), 2) hospitalized children receiving therapeutic doses of APAP (n=10) and 3) children hospitalized for APAP overdose (n=8). Out of 147 miRNAs detected in the APAP overdose group, eight showed significantly increased median levels in serum (miR-122, -375, -423-5p, -30d-5p, -125b-5p, -4732-5p, -204-5p, and -574-3p), compared to the other groups. Analysis of urine samples from the same patients had significantly increased median levels of four miRNAs (miR-375, -940, -9-3p and -302a) compared to the other groups. Importantly, correlation of peak serum APAP protein adduct levels (an indicator of the oxidation of APAP to the reactive metabolite N-acetyl-para-quinone imine) with peak miRNA levels showed that the highest correlation was observed for serum miR-122 (R=0.94; p<0.01) followed by miR-375 (R=0.70; p=0.05). CONCLUSION: Our findings demonstrate that miRNAs are increased in children with APAPtoxicity and correlate with APAP protein adducts, suggesting a potential role as biomarkers of APAPtoxicity. Published by Elsevier Inc.
Authors: Mitchell R McGill; Matthew R Sharpe; C David Williams; Mohammad Taha; Steven C Curry; Hartmut Jaeschke Journal: J Clin Invest Date: 2012-03-01 Impact factor: 14.808
Authors: Xi Yang; James Greenhaw; Qiang Shi; Zhenqiang Su; Feng Qian; Kelly Davis; Donna L Mendrick; William F Salminen Journal: Toxicol Sci Date: 2011-11-22 Impact factor: 4.849
Authors: P J Starkey Lewis; M Merz; P Couttet; O Grenet; J Dear; D J Antoine; C Goldring; B K Park; J G Moggs Journal: Clin Pharmacol Ther Date: 2012-07-25 Impact factor: 6.875
Authors: Jessica A Weber; David H Baxter; Shile Zhang; David Y Huang; Kuo How Huang; Ming Jen Lee; David J Galas; Kai Wang Journal: Clin Chem Date: 2010-09-16 Impact factor: 8.327
Authors: A H Harrill; J Roach; I Fier; J S Eaddy; C L Kurtz; D J Antoine; D M Spencer; T K Kishimoto; D S Pisetsky; B K Park; P B Watkins Journal: Clin Pharmacol Ther Date: 2012-06-27 Impact factor: 6.875